AstraZeneca PLC is 96.1x more valuable than Arcus Biosciences, Inc. by market capitalization ($286.27 B vs $2.98 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RCUS | AZN |
|---|---|---|
| Market cap | $2.98 B | $286.27 B |
| US-listed rank | #1824 | #45 |
| Revenue (latest FY) | $247.00M | - |
| Net income (latest FY) | -$353.00M | - |
| Net margin | -142.9% | - |
| SEC filings | 567 | 1,004 |
AstraZeneca PLC is 96.1x more valuable than Arcus Biosciences, Inc. by market capitalization ($286.27 B vs $2.98 B).
Full pages: Arcus Biosciences, Inc. and AstraZeneca PLC, or browse the full rankings.